Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 5 EP applications Mark Frederic Paris Turner has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 17, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12730499

HCV COMBINATION THERAPY

IPC classification:
A61K 31/7125, A61K 31/712, A61K 31/7115, A61K 31/7056, A61K 31/497, A61K 31/454, C12N 15/113, A61P 31/14
Agent:
Mark Frederic Paris Turner, Santaris Pharma A/S
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12784565

PROGNOSTIC METHOD FOR CHECKING EFFICACY OF MICRO RNA-122 INHIBITORS IN HCV+ PATIENTS

IPC classification:
G01N 33/576, C12Q 1/70
Applicant:
Roche Innovation Center Copenhagen A/S
Agent:
Mark Frederic Paris Turner, Roche Innovation Center Copenhagen A/S
Agent:
Charles Thomas Harding, D Young & Co LLP
Status:
PATENT GRANTED
EP15701345

POLY OLIGOMER COMPOUND WITH BIOCLEAVABLE CONJUGATES

IPC classification:
C12N 15/113
Applicant:
F. Hoffmann-La Roche AG
Agent:
Mark Frederic Paris Turner, F. Hoffmann-La Roche AG
Status:
EXAMINATION REQUESTED
EP16757005

LNA-G PROCESS

IPC classification:
C07D 473/18, C12N 15/11
Agent:
Mark Frederic Paris Turner, Santaris Pharma A/S
Status:
Request for examination was made
EP16775667

OLIGONUCLEOTIDE CONJUGATION PROCESS

IPC classification:
A61K 47/55, A61K 47/54
Agent:
Mark Frederic Paris Turner, Roche Innovation Center Copenhagen A/S
Status:
Request for examination was made

Please Sign in to use this feature